A NEW drug for type-1 diabetes has been licensed in America. Teplizumab is the first treatment for the condition since insulin began being used a century ago. It targets one of the root causes of this type of diabetes and can slow the onset of the disease. Better still, the drug could be the herald of a new era in treating the condition.
Dayan, a professor of clinical diabetes and metabolism at Cardiff University, tells “Babbage” producer Jason Hosken why immunotherapy could be a game-changing innovation for diabetes. Beth Baldwin and Harj Singh share personal stories of how the condition has affected their families. And Sanjoy Dutta, chief scientific officer of diabetes research charity JDRF, explains the potential pathways to finding a cure. Alok Jha hosts. Runtime: 41 min
For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.
Listen on: Apple Podcasts | Spotify | Google | Stitcher | TuneIn
Our weekly podcast on China. This week, we examine why a poem written during the Tang dynasty remains one of the country’s most celebrated literary works
In this future-gazing podcast series, we’re debating the key themes that will shape 2023—from geopolitics to climate change to economics
Also on the daily podcast: Indonesia’s ban on extramarital sex and why Wales is a world leader in leeches
Published since September 1843 to take part in “a severe contest between intelligence, which presses forward, and an unworthy, timid ignorance obstructing our progress.”
Copyright © The Economist Newspaper Limited 2022. All rights reserved.